Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncology

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 17263127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

  2006cited by this paper
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response.

  2006cited by this paper
• Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

  2006cited by this paper
• Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.

  2006cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.

  2006cited by this paper
• Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

  2006cited by this paper
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

  2006cited by this paper
• Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

  2006cited by this paper
• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

  2006cited by this paper
• HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy

  2006cited by this paper
• Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

  2006cited by this paper
• HER2 amplification in recurrent breast cancer following breast‐conserving therapy correlates with distant metastasis and poor survival

  2006cited by this paper
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

  2005cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

  2005cited by this paper
• Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Apoptosis induction by trastuzumab: possible role of the core biopsy intervention.

  2005cited by this paper
• Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

  2005cited by this paper
• Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

  2005cited by this paper
• Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

  2005cited by this paper
• Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

  2005cited by this paper
• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

  2005cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

  2005cited by this paper
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

  2004cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

  2004cited by this paper
• Biology of the epidermal growth factor receptor family.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

  2004cited by this paper
• A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.

  2004cited by this paper
• Human cancer, PTEN and the PI-3 kinase pathway.

  2004cited by this paper
• The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition*

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.

  2003cited by this paper
• Her-2/neu and Topoisomerase iiα in Breast Cancer

  2003cited by this paper
• HER-2/neu and topoisomerase IIalpha in breast cancer.

  2003cited by this paper
• Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

  2003cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

  2002cited by this paper
• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.

  2001cited by this paper
• ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

  2000cited by this paper
• Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Requirement for neuregulin receptor erbB2 in neural and cardiac development

  1995cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990influential reference
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

  1985cited by this paper

• Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics

  2026cites this paper
• Achieving health equity in cancer care in the Philippines

  2023cites this paper
• Breast cancer treatment and ovarian function.

  2022cites this paper
• The Ras effector NORE1A forms a tumor suppressor complex with BRCA1.

  2015cites this paper
• Pertuzumab in breast cancer: a systematic review.

  2013cites this paper
• Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers

  2012cites this paper
• Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.

  2012cites this paper
• Novel targeted agents for the treatment of advanced breast cancer.

  2012cites this paper
• Selective targeting of cancer cells with RNA aptamers

  2012cites this paper
• Notch-1 Specifically Activates Erk1/2 in Multiple Breast Cancer Subtypes

  2011cites this paper
• The effects of paclitaxel, dose density, and trastuzumab on treatment‐related amenorrhea in premenopausal women with breast cancer

  2010cites this paper
• Function of the anterior gradient protein family in cancer

  2009cites this paper
• Evolving novel anti-HER2 strategies.

  2009cites this paper
• Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.

  2009cites this paper
• Toward Personalized Therapy for Cancer

  2008cites this paper
• Personalized Medicine for Cancer

  2008cites this paper
• The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?

  2007cites this paper